

SAMANTHA DICKSON BRAIN TUMOUR TRUST (COMPANY LIMITED BY GUARANTEE)

ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2011

Registered charity no. 1128354 Company registration no. 05615995

Index

Page	
2	Trust Information
3	Report of the Trustees
10	Statement of the Trustees' Responsibilities
12	Independent Auditor's Report
14	Statement of Financial Activities
15	Balance Sheet
16	Notes to the Financial Statements

Reference and Administrative Information

Trustees

Neil A Dickson (Chairman) Graham Norton (Vice Chair)

Angela J Dickson
Peter G McDermott
Berendina Norton

Alistair Nunn (resigned March 2011)

Lady Alison Wakeham

Philippa Murray Peter Unsworth Gavin St Pier

Andrew Silver (resigned September 2010)

Ann Gales Shirley Barnfield Aidan Lisser

Chief Executive Officer

Paul Carbury (to March 2011)

Sarah Lindsell (from May 2011)

Company Secretary

Paul Carbury (to March 2011) Carole Dear (from April 2011)

Registered Charity Number: 1128354 Registered Company Number: 05615955

Principal Office

Saddlers House 100 Reading Road

Yateley

Hampshire GU46 7RX

Auditors Legal Advisors

haysmacintyre Bates, Wells and Braithwaite LLP

Fairfax House Scandinavian House 15 Fulwood Place 2 - 6 Canon Street

London London WC1V 6AY EC4M 6YH

Bankers

Lloyds Bank Plc Bank of Scotland CCLA Investment Management Ltd

174 Fleet Road,2 City Place,COIF Charity FundsFleetBeehive Ring Road80 CheapsideHampshireGatwickLondonGU13 8DDRH6 0PAEC2V 6DZ

Report of the Trustees

The trustees, who are also directors of the charity for the purpose of Companies Act, present their annual report and financial statements of the charity for the year ended 31 March 2011. The Trustees confirm that the annual report and financial statements of the charitable company comply with current statutory requirements, the requirements of the charity's governing document and the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by charities' issued in 2005.

The trustees confirm that they have complied with the duty in section 4 of the Charities Act 2006 to have due regard to the public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.

Structure, Governance and Management

Samantha Dickson Brain Tumour Trust is a registered charity, number 1128354, which was incorporated on 8th November 2005 and is governed by its memorandum and articles of association.

The trustees who served during the year are set out on Page 2. Trustees are appointed by a resolution passed at a meeting called by the Chairman and any two trustees. During the year, two trustees, Mr Andrew Silver and Dr Alistair Nunn resigned for personal reasons and continue to support the Trust in other ways.

The trustees meet at least three times per year and agree the broad strategy and areas of activity for the Trust including research strategy, approval of research grants, patient support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All trustees give of their time freely and no trustee remuneration was paid in the year. Details of trustee expenses are disclosed in Note 6 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and in accordance with the Trust's policy withdraw from decisions where a conflict of interest arises.

Day to day operations and management are delegated to the Chief Executive and Senior Management Team who provide regular reports to the trustees on performance and operations.

The Trust also benefits from four sub-committees which have been established to advise on key areas of activity. These are:

- Finance and Fundraising Sub-Committee
- · Research Sub-Committee
- Patient Support Sub-Committee
- · Grant Review and Monitoring Committee

The Trust is supported by over 300 international reviewers from around the world who undertake peer review assessments of research grant applications and make recommendations to the Grant Review and Monitoring Committee (GRAM).

The GRAM is made up of eleven international brain and cancer specialists and two lay people personally affected by brain cancer. The GRAM assesses peer reviewers scores and comments on grant applications and advises the Board of Trustees on the scientific merit of each proposal so informed funding decisions can be made. This process enables Trustees to select only the most high quality research projects for funding. GRAM members give their time for free, and we are extremely grateful to them for their contribution to our work. The GRAM is made up of the following members:

Name

Dame Ingrid Allen (Chair) Professor Jillian Birch Professor Steven Clifford Professor V Peter Collins Dr Stephen Falk

Institution/lay member Queens University Belfast

University of Manchester University of Newcastle Cambridge University Bristol Oncology Centre

Annual Report and Financial Statements for the Year Ended 31 March 2011

Dr Michelle Garrett Institute of Cancer Research (in partnership with Royal

Marsden NHS Foundation Trust)
Institut Gustave Roussy, France

Dr Jacques Grill Institut Gusta Mr Steven Jones Lay member

Dr John Mason University of Edinburgh Professor Monica Nistér Karolinska Institutet, Sweden

Mrs Clare Normand Lay member

Professor Roy Rampling Glasgow and Western Infirmary

Professor Richard Wise Cardiff University

Umbrella and Friends groups also remain an integral part of the Trust and are at the heart of what we do. Families and friends who have lost either a loved one to a brain tumour or where a loved one is recovering from or is living with a brain tumour start Umbrella and Friends groups. We have 74 such groups across the UK and in the past year they have raised nearly £303,000 of the Trust's overall income which is a tremendous achievement.

Umbrella and Friends groups are also entirely volunteer led and they put in thousands of voluntary hours each year to raise much needed awareness and funds for brain tumour research and patient support.

The Trust is a longstanding member of the Association of Medical Research Charities (AMRC). The AMRC is an umbrella organisation of the leading medical and health research charities in the UK. The Trust aims to follow the highest standards of accountability in medical and health research funding, and membership of AMRC requires the use of independent peer review in the allocation of all grants and awards for research. The Trust has received a best practice award for its peer review process.

The Trust is also a member of the Fundraising Standards Board and is represented on a number of influential bodies and cancer campaigning groups.

Risk Assessment

The trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Finance and Fundraising Sub-Committee review governance and risk on a quarterly basis and make recommendations on best practice to the trustees.

Aims and Objectives

The charitable objects of the company are:

- To promote research into the causes and treatment of brain cancer with particular reference to childhood brain tumours on terms that the results of such research are published
- The relief of sufferers of brain cancer by providing support services to them and their families

The Trust's objectives are achieved by awarding research grants to scientific institutions and offering practical support to patients and carers through a telephone helpline, a programme of patient centred events and provision of information.

In May 2010, at the annual strategy session, the trustees agreed three new strategic objectives in order to achieve our charitable aims and set key performance indicators to monitor our performance in pursuit of our objectives.

The three strategic objectives and key performance indicators that were agreed for future years are:

Objective One

We will fund research projects that will help us understand how brain tumours start and develop and which will improve survival rates and quality of life for people who are diagnosed.

We will achieve this goal by:

Annual Report and Financial Statements for the Year Ended 31 March 2011

- Working in collaboration to develop our Centre of Excellence model that will incorporate basic and translational research, clinical trials and brain tumour banking
- Investing in clinical trials and their infrastructure to enable novel treatments to be developed
- Continuing to fund our existing portfolio of research projects directed at improving understanding, diagnosis and treatment of brain tumours

Objective Two

We will provide people who are diagnosed with brain tumours, their families and carers, with the support and information they need.

We will achieve this goal by:

- Operating a national brain tumour helpline and email information service for patients, families and carers
- Providing information (including details of clinical trials) in treatment centres, at events and online
- Organising a series of patient centred events across the UK
- Publishing the results of our research to patients, carers and the media
- Evaluating the impact of our service and conducting research into the needs of beneficiaries

Objective Three

We will raise awareness of brain tumours and campaign for better outcomes for patients and their families and carers.

We will achieve this goal by:

- Raising awareness of the signs and symptoms of brain tumours amongst GPs, other health professionals and the general public to encourage early diagnosis and detection
- Engaging with politicians and policy makers through the All Party Parliamentary Group on Brain Tumours
- Developing our brand and communicating the needs of brain tumour patients and their carers through stand-alone awareness raising and fundraising campaigns

Grant Making Policy

The Trust has established its grant making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

Approximately 8,500 people are diagnosed with a primary brain tumour each year and 3,500 sadly lose their lives. Brain cancer is now the biggest killer of children under 15 and young adults under 40 than any other cancer. Increasingly there are thousands of people who are diagnosed with a secondary brain tumour (estimates are a further 8,000 people per year), where the cancer has spread from other parts of the body.

The beneficiaries of our grant making programme are ultimately people with brain tumours and their families and carers. We believe that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Trust invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. The Trust is a member of the Association of Medical Research Charities and seeks to follows best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research and continuation of the grants is subject to annual assessment by our Research Sub-Committee and Grant Review and Monitoring Committee supported by the Head of Research. In all cases, continuation of

Annual Report and Financial Statements for the Year Ended 31 March 2011

funding is subject to the research undertaken being in the interests of the Trust and a progress assessment that is satisfactory.

Achievements and Performance

During 2010/11 we increased our income to over £1,828,492 (a 20% increase) a record year for fundraising and invested £1,419,072 in our research, patient support programmes and raising awareness.

The Trust makes a unique contribution to the brain tumour community and our performance against what we said we would do is detailed below:

1 We said we would continue our significant investment in research and patient support programmes

We achieved this by:

- Invested £1,149,115 in our brain tumour research programme in 17 projects helping to increase our understanding of the disease
- · Funded 22 leading scientists across the UK
- Invested £225,239 in patient support enabling us to support 1226 people with brain tumours and their families
- We said we would commit the second instalment of £375,498 at the Samantha Dickson Brain Cancer Unit at UCL Cancer Institute

We achieved this by:

- Investing for a second year in UCL to a value of £375,498
- 3 We said we would fund clinical trials in our partnership with Cancer Research UK

We achieved this by:

- Investing £75,480 in two clinical trials at the University of Cambridge and the Royal Victoria Infirmary, Newcastle which was matched by £75,480 funding from Cancer Research UK
- Funding, with Cancer Research UK, a Clinical Trials Officer for a second year at University
 College London with funds of £26,273, to promote and support clinical trials among clinicians
- We said we would set up and deliver the Brain Cancer Care Project funded by a Big Lottery Fund grant of £236,977 which will support more brain tumour patients and their families over the next three years

We achieved this by:

- Employing an Education Manager, funded by the grant, to oversee and manage the project which aims to provide support to brain tumour patients and their carers via a national helpline, information roadshows and online
- In the first 6 months of the project up to the end of March 2011 we have supported 82 families living with or affected by brain tumours and answered 975 calls
- We said we would deliver the next stage of the childhood early diagnosis project in partnership with Royal College of Paediatrics and Child Health and Children's Brain Tumour Research Centre

We achieved this by:

Completing the feasibility, development and set-up phase. This involved appointing a PR
agency, website designer and conducting a public and professional survey to test awareness
of the signs and symptoms of childhood brain tumours. We have set a public launch date for
June 2011; the project aims to reduce the time it takes for a childhood brain tumour to be
diagnosed from 12 weeks to 6 weeks over the next three years

6 We said we would provide specialist support to families and children with brain tumours

We achieved this by:

- Thanks to support from BBC Children in Need we were able to appoint a Telephone Helpline
 and Information Worker who has continued to provide support to families and children through
 our National Helpline and the provision of family support days. This year we supported 64
 children and families.
- We said we would roll out our programme of patient information events to new geographical locations

We achieved this by:

- Delivering information events to 430 people in the following locations: Belfast, Glasgow, Cardiff, Southampton, London and Dogmersfield. An information roadshow is a free to attend, local all day event where people living with or affected by brain tumours can access support and up to date information on research and treatments.
- 8 We said we would raise at least £100,000 from our gala Dorchester Fundraising Ball to fund additional research

We achieved this by:

- Organising the Dorchester Ball on the 13 November 2010. The total income for the event was £180,000, we spent £60,000 on organising the event, leaving a surplus of £120,000.
- The surplus has enabled us to commit to additional research and patient support expenditure that wouldn't otherwise have been possible.
- We said we would secure an increase in grant income through the establishment of a trusts fundraising programme

This was not achieved due to the economic climate and increased competition in the market place.

10 We said we would provide support to and marketing of Umbrella and Friends groups

We achieved this by:

- Producing a fundraising toolkit for all umbrella groups to help them maximise their fundraising efforts
- We also introduced tailored communications to update Umbrella and Friends Groups on the progress of the research projects they are helping fund
- During the year the number of Umbrella/Friends Groups increased from 65 to 74

11 We said we would improve communications and administration with our donors and supporters

We achieved this by:

- Establishing a training programme for staff on customer service and implementing a
 programme of regular updates and a twice yearly newsletter with information on research and
 patient support
- Attracting significant media coverage throughout the year.

12 We said we would develop our website to attract more beneficiaries and fundraisers

We partly achieved this by:

- Reviewing and editing website content to make it more appealing to donors and patients
- We improved our Google rankings and secured a Google Grant to help us achieve this
- We delayed the development of online forums for patients and carers until 2011/12 to tie in with a planned design re-fresh of the website www.braintumourtrust.co.uk

Finance Review

Incoming resources for the year were £1,828,492 compared with £1,410,370 in the previous year. Expenditure for the year was £1,788,081 compared with £1,436,515 in the previous year.

During the year we added a number of new research grants to our portfolio which will see us invest £1,575,314 over the next 3 years in much needed brain tumour research.

Reserves Policy

The reserves policy of the charity is to maintain unrestricted funds equal to three months operational costs which at present level is £485,807. The present level of free reserves of £490,487 is made up of total reserves less restricted funds, designated funds and net book value of assets (2010 - £443,526).

Funds are held in interest deposit accounts and these are reviewed by the Finance and Audit Sub-Committee on a quarterly basis. During the year the Trustees reviewed the cash on deposit and transferred £600,000 of funds to higher interest accounts.

The joint Finance and Fundraising Committee meet on a quarterly basis to review income, expenditure and all other financial issues, including risk, and report back to the main Board of Trustees.

Fundraising

Our Umbrella and Friends Groups who are raising funds mostly in memory of a loved one, contributed 20% of the Trust's income. This is a tremendous achievement and our heartfelt thanks go out to all those who work tirelessly for the cause.

During the year we were the beneficiaries of 6 legacies totalling £215,809. We also organised a successful Fundraising Ball at the Dorchester Hotel which netted a surplus of £120,000. This event was attended by a number of our Patrons, many of whom donated special auction prizes, including Dawn French, Earl Spencer, Jonny Wilkinson, Alastair Stewart, Chris de Burgh, Hayley Mills, Fiona Fullerton, Sandy Lyle and Tom Daley and we are also grateful for the generous sponsorship provided by Traffic Names.

We have analysed the overlying trends on core income streams from the previous two years which contain the most reliable data. Community fundraising, SDBTT events fundraising, grants fundraising are on an upwards trajectory, memorial donations and donations from individuals are on a downward trend. During the year investment income was £7,036.

For 2011/12 trustees have agreed a new fundraising strategy to ensure continued growth and enable us to raise sufficient funds to support our research and patient support work.

Scientific and Medical Advisory Board

In addition to the GRAM the Trust continues to be supported by its Scientific and Medical Advisory Board (SMAB) which advises on research policy, undertakes peer review assessments of research grant applications and provides a valuable resource on the latest developments in brain tumour research. The SMAB is made up of the following members:

UK Members

Rachel MacArthur Clinical Nurse Specialist, King's College Hospital, London

Prof Dame Ingrid Allen
Prof Geoffrey J Pilkington
Prof John L Darling
Prof Mike Brada
Dr Janice Royds
Prof Ian R Whittle

MB Bch BAO DSc, Queen's University, Belfast
BSc PhD CBiol FRCPath, University of Portsmouth
BSc PhD, University of Wolverhampton
BSc FRCP FRCR, Royal Marsden Hospital, Sutton
BSc PhD, University of Sheffield Medical School
MD PhD, Western General Hospital, Edinburgh

Prof Patricia A McKinney BSc PhD, University of Leeds

Prof V Peter Collins MD FRCPath, Addenbrooke's Hospital, Cambridge

Prof David A Walker BmedSci BM BS FRCP FRCPCh, Queen's Medical Centre, Nottingham

Dr Jeremy Rees BSc MB BS FRCP PhD, University College London Prof Roy Rampling PhD FRCR FRCP, Western Infirmary, Glasgow

Prof P Lantos MD PhD DSc AcadMed.Sci FRCPath, University of Bristol

Dr David Levy BSc FRCR FRCP, Weston Park Hospital, Sheffield

Dr Antony Michalski MB ChB PhD MRCP, Great Ormond Street Hospital, London

Prof Steven Clifford MD PhD, University of Newcastle Dr Lynn Kilbride PhD, Napier University, Edinburgh

European Members

Prof Zvi Ram Tel Aviv Medical Centre, Israel

Prof Roger Stupp MD, University of Vaudois, Switzerland

Prof Dr Jorg-Christian Tonn
Prof Bengt Westermark
Dr John G Wolbers
University of Munich, Germany
University of Uppsala, Sweden
Erasmas University, Netherlands

Dr Jiri Ehrmann MD PhD, Palacky University, Czech Republic

Prof MJ van de Bent MD, University Medical Centre Rotterdam, Netherlands

Prof Rolf Bjerkvig University of Bergen, Norway Prof Monica Nister Karolinska Institutet, Sweden

Patrons

We would also like to pay a special thank you to our many patrons. During the year Tom Daley, Alastair Stewart, Fiona Fullerton, Seamus Cullen and Earl Spencer also very kindly made public appearances on behalf of the Trust. We would also like to welcome Professor Roy Rampling into his new role at SDBTT as Patron with a special brief as scientific and clinical advisor. Our other patrons are as follows:

Dawn French; Jonny Wilkinson; Chris de Burgh; Julia Somerville; Stephen Hendry; Sandy Lyle; Sir Thomas Lighton; Michael Crawford; Dame Helen Mirren; Leslie Thomas; Twiggy Lawson; Delia Smith; Martin Amis; Hayley Mills; Ciara Janson; Christopher Bailey and Gayle McDermott.

Plans for the Future

Samantha Dickson Brain Tumour Trust is the UK's largest brain tumour charity and its leading funder of brain tumour research. For 2011/12 the trustees have set some key objectives that will help us achieve our charitable aims. These are:

Annual Report and Financial Statements for the Year Ended 31 March 2011

1 Continue our investment in research and patient support programmes 2 Commit the third instalment of £357,633 at the Samantha Dickson Brain Cancer Unit at UCL Cancer Institute Continue to expand our clinical trials portfolio in partnership with other charities and 3 Organise an SDBTT Research Conference and produce an Impact Report on what 4 difference our research funding has made Evaluate the 1st year of the Brain Cancer Care Project and report back to funders and 5 beneficiaries 6 Launch the Headsmart Campaign to reduce the time it takes for childhood brain tumours to be diagnosed 7 Update and publish online our brain tumour information leaflets and booklet for children by children 8 Continue to deliver our programme of patient information events to new geographical locations 9 Secure an increase in total fundraising income by implementing a new fundraising strategy 10 Re-fresh the design of the website and develop online patient and carer forums and message boards

Statement of the Trustees Responsibilities

The trustees (who are also directors of the Samantha Dickson Brain Tumour Trust for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time of the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware;
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The report of the Trustees has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Neil Dickson, Chair of Trustees

Independent Auditors Report to the Members of the Samantha Dickson Brain Tumour Trust

We have audited the financial statements of Samantha Dickson Brain Tumour Trust for the year ended 31 March 2011 which comprise of the primary statements such as the Statement of Financial Activities, Balance Sheet, and related notes. The financial reporting framework that has been applied in their preparation is applicable law and the Financial Reporting Standard for Smaller Entities (effective April 2008) (United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

Respective responsibilities of Trustees and auditors

As explained more fully in the Statement of Trustees' Responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Trustees; and the overall presentation of the financial statements. In addition, we read all the financial; and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2011 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- · the financial statements are not in agreement with the accounting records and returns; or
- · certain disclosures of trustees' remuneration specified by law are not made; or
- · we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the Trustees' Report.

Bernie Watson

Senior Statutory Auditor

for and on behalf of haysmacintyre, Statutory Auditors

Fairfax House 15 Fulwood Place London, WC1V 6AY

Date: 21 October 251.

Samantha Dickson Brain Tumour Trust Statement of Financial Activities For the Year Ended 31 March 2011

ı	Notes	Unrestricted Funds £	Restricted Funds £	Total 2011 £	Total 2010 £
Income and Expenditure					
Incoming Resources					
Incoming resources from generate	d funds				
Voluntary income	2	1,135,454	7,767	1,143,221	1,026,551
Activities for generating funds	3	330,080	-	330,080	67,191
Investment income		6,987	49	7,036	15,730
Grants receivable	4	-	348,155	348,155	300,898
Total Incoming Resources		1,472,521	355,971	1,828,492	1,410,370
Resources Expended	5				
Costs of generating funds					
Costs of generating voluntary income		336,942	-	336,942	264,133
Charitable activities					
Research costs		881,899	267,216	1,149,115	944,146
Patient support		135,014	90,225	225,239	189,432
Campaigning & raising awareness		44,718	-	44,718	-
Governance costs	6				
Management and administration		32,067	-	32,067	38,804
Total Resources Expended		1,430,640	357,441	1,788,081	1,436,515
(Expenditure)/Income before tra	nsfers	41,881	(1,470)	40,411	(26,145)
Net transfers between funds		-	-	-	-
Net (expenditure)/income after t	ransfers	41,881	(1,470)	40,411	(26,145)
Reconciliation of Funds Balances at 1 April 2010		460,493	118,379	578,872	605,017
Balances at 31 March 2011		502,374	116,909	619,283	578,872

The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities. The notes on pages 16 to 24 form part of the financial statement

	Notes	£	2011 £	£	2010 £
Fixed Assets Tangible fixed assets	9		11,887		16,967
Current Assets Debtors Cash at bank	10 -	162,536 1,839,168		106,656 1,805,001	
Creditors:	11	2,001,704		1,911,657	
Amounts Falling Due Within One Year Net Current Assets		1,394,308	607,397	1,349,752	561,905
Total Assets Less Current Lia	bilities		619,283		578,872
Funds Unrestricted Funds General funds Designated funds	15	502,374	502,374	456,769 3,724	460,493
Restricted Funds		116,909	116,909		118,379 578,872

The financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

The financial statements were approved by the Trustees on 2 (October 2011 and signed on their behalf by:

Neil Dickson

Chairman of Trustees

The notes on pages 16 to 24 form part of these financial statements.

Notes to the Financial Statements for the Year Ended 31 March 2011

1 Accounting Policies

(a) Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention. The financial statements have been prepared in accordance with the Statement of Recommended Practice "Accounting and Reporting by Charities" issued in March 2005, and in accordance with the Financial Reporting Standards for Smaller Entities (effective April 2008), applicable accounting standards and the Companies Act 2006.

(b) Company status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 2. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) Incoming Resources

All incoming resources are included in the Statement of Financial Activities when the company is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fund-raising events from private individuals and sponsors are taken into account on the basis of cash receipts. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest is accounted for on an accruals basis.

Where services and facilities are provided to the charity as a donation that would normally be purchased from our suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to the charity.

(d) Resources Expended

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent.

Support costs are those costs incurred directly in support of expenditure in the objects of the Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling the Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the Trustees in the discharge of their statutory duties.

(e) Stocks

Stocks of publicity materials have been donated to the charity and have no carrying value at the balance sheet date.

(f) Fund Accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

(g) Fixed assets

The cost of tangible fixed assets is their purchase cost, together with incidental expenses of acquisition. Tangible fixed assets under £500 are not capitalised.

(h) Depreciation

Depreciation is charged on a straight-line basis at such a rate as will cause the assets to be written off in the books of the company at the end of their useful working life. The rates used are as follows:

Computer equipment 33% Office equipment 20%

(i) **Donated Assets and Services**

Where services or assets are provided to the charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to the charity.

(i) Operating Lease

The charity classifies the lease of Saddlers House as an operating lease. Rental charges are charged on a straight line basis over the term of the lease (5 years).

(k) Cash Flow

The financial statements do not include a cash flow statement because the charitable company as a small reporting entity, is exempt from the requirement to prepare such a statement under the Financial Reporting Standard for Smaller Entities (effective April 2008).

(I) Pensions

The charitable company operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from the charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by the charity and are accounted for on an accruals basis.

2 **Voluntary Income**

_	voiditary income	2211	00.40
		2011	2010
		£	£
	Memorial donations	106,872	118,222
	Merchandise	14,093	11,593
	Donor marketing	5,410	19,352
	Fundraising	512,242	393,462
	Gift Aid	91,762	104,944
	Trusts	52,223	189,190
	Individual donations	144,810	189,788
	Legacies	215,809	
		1,143,221	1,026,551
3	Activities for Generating Funds		
J	Activities for Scherding Funds	2011	2010
		£	£
	Events	330,080	67,191
	Events	330,060	67,191
4	Grants receivable		
		2011	2010
		£	£
	GlaxoSmith Kline	-	148,966
	Brian Cross Memorial Trust	67,795	64,566
	BBC Children in Need	28,367	29,004
	Bernard Sunley	7,500	-
	Childwick Trust	15,000	16,000
	T & J Meyer Family Foundation	15,000	-
	University of Nottingham/Health Foundation	20,427	12,267
	Cancer Research UK	10,509	10,208
	Big Lottery Fund	78,019	-
	Roald Dahl Foundation	10,000	-
	Rosetrees Trust	10,000	-
	Joseph Foote Charitable Trust	57,138	-
	Others	28,400	19,887
		348,155	300,898
_	Analysis of December Evyended		

5 Analysis of Resources Expended

Payable Costs Costs 2011 2010)
£ £ £ £	
Fundraising - 319,526 17,416 336,942 264,1	133
Research Costs 12a 943,105 146,614 59,396 1,149,115 944,1	146
Patient Support - 213,597 11,642 225,239 189,4	432
Campaigning & raising awareness - 42,407 2,311 44,718 -	
Governance 6 <u>- 30,409</u> 1,658 32,067 38,8	804
943,105 752,553 92,423 1,788,081 1,436,5	515

Support costs represent general office overheads such as staff costs, stationery, travel and telephone costs.

Support Costs

	Research Costs £	Patient Support £	Campaigning & raising awareness £	Fundraising £	Governance £	Total £
Rent, rates	20,748	4,067	807	6,084	579	32,285
PPS, Computer exp	20,236	3,967	787	5,934	565	31,489
Operating costs	7,175	1,406	279	2,104	200	11,164
Financial costs	10,697	2,097	416	3,137	299	16,646
Professional	540	105	22	157	15	839
- -	59,396	11,642	2,311	17,416	1,658	92,423
=						

Where possible, these have been allocated directly to activities and remaining support costs have been attributed to different departments in proportion to the direct costs.

6 **Governance Costs**

	Total	Total
	2011	2010
	£	£
Auditors remuneration	8,131	7,708
Premises costs and insurances	2,591	2,064
Trustee meeting & recruitment advertising costs	3,556	8,835
Legal and professional	967	8,189
Support costs	1,658	2,038
Staff	15,164	9,969
	32,067	38,803

Trustees received no remuneration (2010: £nil) but one was reimbursed for expenses in the year (2011: £407) (2010: £156). The premium in respect of professional liability insurance covering trustee indemnity was £685 (2010: £1,486). Audit fees amounted to £6,920 plus VAT for the year (2010: £6,300 plus VAT).

7 Net Incoming/(Outgoing) Resources for the Year

	2011	2010	
	£	£	
Auditors' remuneration	8,131	7,708	
Depreciation	10,153	16,496	
Pension costs	20,998	10,180	

8 Staff costs

	2011	2010
The aggregate payroll costs of the above were:	£	£
Wages and salaries	355,911	303,181
Social security costs	36,298	30,813
Pension	20,998	10,180
Other staff costs	-	26,144
	413,207	370,318

The average number of full time equivalent employees during the year was as follows:

	2011	2010
Administrative staff	1	4
Direct staff	5	5
Marketing staff	4	2
Support staff	2	1
	12	12

One employee received remuneration amounting to between £60,000 and £70,000 in the year. In addition the eomployer's pension contributions were £3,357.

9	Tangible Fixed Assets		(Computer/Office Equipment £
	Cost At 1 April 2010 Additions At 31 March 2011			68,231 5,073 73,304
	Depreciation At 1 April 2010 Charge for period At 31 March 2011			51,264 10,153 61,417
	Net Book Value At 31 March 2011 At 31 March 2010			11,887 16,967
10	<u>Debtors</u>		2011 £	2010 £
	Gift Aid Prepayments and accrued income Other debtors Debtors		3,119 8,372 150,989 56 162,536	41,029 8,102 44,491 13,034 106,656
11	Creditors: Amounts due within one year	Notes	2011 £	2010 £
	Grants Payable Accruals Creditors Other Creditors	12b	1,127,872 9,394 256,952 90 1,394,308	1,047,366 9,284 293,001 101 1,349,752

12	Grants Fayable	2011	2010
(2)	The amount payable in the year comprises:	£	£
(a)	The amount payable in the year comprises.	~	2
	Queen Mary University of London - Prof. D. Sheer 4/43	<u>-</u>	65,291
	Royal Marsden - Dr. N. Al-Saffar 6/54	_	81,462
	Royal Marsden - Dr. C. Jones 6/78	55,000	-
	Institute of Cancer Research - Dr. L. Chesler 6/88	76,468	_
	Institute of Neurology - Dr. T. Warr 8/34	-	(43,761)
	Institute of Neurology - Prof. S. Brandner 8/35	(1,930)	2,280
	UCL Centre of Excellence - Prof. P. Salomoni 8/47	272,816	314,300
	Institute of Neurology - Dr. T. Warr 8/50		(9,676)
	Institute of Neurology - Prof. S. Brandner 8/51	26,000	19,142
	NCRI Project Office r- Dr. C. Short 8/56	36,782	20,416
	UCL Centre of Excellence - Dr. S. Pollard 8/105	102,682	21,051
	University College London - Dr. P. Watts 8/108	24,694	,
	University of Cambridge - Prof. V. P. Collins 10/29	,	(647)
	University of Cambridge - Dr. K. Ichimura 10/33	_	(15,877)
	University of Cambridge - Prof. V. P. Collins 10/36	_	(1,536)
	Univesity of Cambridge - Dr. H. Ring 10/45	_	41,700
	University of Cambridge - Prof. V. P. Collins 10/106	50,880	48,345
	University of Edinburgh - Dr. R. Grant 11/52	59,864	(11,485)
	University of Leeds - Prof. P. McKinney 13/42	-	7,530
	University of Leicester CCLG 14/27	_	28,619
	University of Leicester CCLG 14/28	_	(14,386)
	University of Newcastle - Dr. S. Clifford 16/46	_	60,630
	University of Newcastle - Dr. S. Clifford 16/49	14,014	_
	University of Newcastle - Dr. S. Clifford 16/92	64,110	_
	University of Newcastle - Dr. S. Clifford 16/97	20,580	26,954
	University of Newcastle - Dr. S. Bailey 16/107	12,974	, -
	University of Nottingham - Prof. R. Grundy 17/24	, -	583
	University of Nottingham - Dr. P. Scotting 17/30	-	(18,108)
	University of Nottingham - Prof. R. Grundy 17/31	-	52,691
	University of Nottingham - Prof D. Walker 17/39	-	(11,046)
	University of Nottingham - Prof. R. Grundy 17/40	(296)	(743)
	University of Nottingham - Prof. R. Grundy 17/53	42,954	57,768
	University of Nottingham - Prof. R. Grundy 17/86	57,138	, -
	University of Nottingham - Prof D. Walker 17/109	16,000	_
	University of Southampton - Dr. C. Kennedy 20/23	12,375	2,297
	University of Wolverhampton - Prof. J. Darling 21/22	-	(5,000)
	University of Wolverhampton - Dr W. Wang 21/44	-	38930
		040 405	757.704
		943,105	757,724

	2011	2010
(b) Reconciliation of grants payable	£	£
Commitments accrued at 1 April 2010	1,047,366	973,505
Grants payable for the year	943,105	757,724
Grants paid during the year	(862,599)	(683,863)
Commitments accrued at 31 March 2011	1,127,872	1,047,366

(c) The total commitments authorised which are subject to the recipient fullfilling certain conditions but not accrued as expenditure were as follows:

	2011	2010
	£	£
Institute of Neurology (Prof S Brandner) 8/51	-	26,000
University of Nottingham (Prof R Grundy) 17/53	-	43,857
Royal Marsden (Dr N Al-Saffar) 6/54	86,776	86,776
University of Edinburgh (Dr R Grant) 11/52	60,000	120,000
UCL Centre of Excellence (Prof P Salomoni) 8/47	686,462	959,278
UCL Centre of Excellence (Dr S Pollard) 8/105	270,200	372,882
University of Cambridge (Prof VP Collins) 10/106	49,741	100,621
Royal Marsden (Dr L Chesler) 6/88	60,965	-
Newcastle University (Prof S Clifford) 16/92	137,088	-
Royal Marsden (Dr C Jones) 6/78	74,033	-
University of Nottingham (Prof R Grundy) 17/86	112,237	-
Clinical trial (Dr C Watts) 8/108	24,737	-
Clinical trial (Dr S Bailey) 16/107	13,075	-
	1,575,314	1,709,414

Of this amount £849,348 (2010: £643,011) is due within one year.

13 **Operating Lease Commitments**

At 31 March 2011 the charity had annual commitments under non-cancellable leases as follows:

	Expiry date		2011 £	2010 £	
	Between two and five years		28,000	28,000	
			28,000	28,000	
14	Analysis of Net Assets Between Funds				
		Unrestricted	Restricted	Total	Total
		Funds	Funds	Funds	Funds
				2011	2010
		£	£	£	£
	Tangible fixed assets	11,887	-	11,887	16,967
	Debtors and accrued income	37,569	124,967	162,536	106,656
	Cash at bank	1,743,317	95,851	1,839,168	1,805,001
	Creditors and accrued expenses	(1,290,399)	(103,909)	(1,394,308)	(1,349,752)
		502,374	116,909	619,283	578,872

15 **Funds**

	Balance at 01.04.10	Incoming Resources	Resources Expended	Transfers	Balance at 31.03.11
	£	£	£	£	£
Restricted Funds					
GlaxoSmith Kline	100,621	-	(50,880)	-	49,741
Astro Fund Support	1,064	6	-	-	1,070
Support Group - Bernard Sunley	6,885	7,543	(7,901)	-	6,527
Garnett Charitable Trust	-	500	(500)	-	-
The Waterloo Foundation	-	2,450	(2,450)	-	-
Gloag Foundation	-	1,500	(1,500)	-	-
Jarvis (Harpenden) Charitable Trust	-	300	(300)	-	-
Hedley Foundation	-	3,000	(3,000)	-	-
Childwick Trust	-	15,000	(15,000)	-	-
Brian Cross Memorial Trust	-	67,795	(67,795)	-	-
P F Charitable Trust	-	5,000	-	-	5,000
Toy & Hobby Trust	2,309	-	(2,309)	-	-
Oligodendroglioma Research Fund	-	2,617	(2,617)	-	-
Broyst Foundation	2,500	2,500	(2,758)	-	2,242
C Charitable Trust	5,000	3,000	(5,000)	-	3,000
BBC Children in Need	-	28,367	(28,367)	-	-
Hunmanby Cancer Fund	-	900	(900)	-	-
Catherine Cookson Trust	-	3,000	(3,000)	_	-
Cancer Research UK	-	10,509	(10,509)	-	-
University of Nottingham	-	20,427	(20,427)	-	-
Roald Dahl Foundation	-	10,000	(6,273)	-	3,727
Big Lottery Fund	-	78,019	(35,167)	-	42,852
T J Meyer Family Foundation	-	15,000	(15,000)	-	-
David Muir	-	5,000	(5,000)	-	-
Lynn Foundation	-	500	(500)	-	-
Vodafone Foundation	-	2,750	-	-	2,750
Rosetrees Trust	-	10,000	(10,000)	-	-
Joseph Foote Charitable Trust	-	57,138	(57,138)	-	-
Frognal Trust	-	3,000	(3,000)	-	-
Vinci Plc	-	150	(150)	-	-
	118,379	355,971	(357,441)		116,909
Unrestricted Funds					
General Fund	456,769	1,472,521	(1,426,916)	-	502,374
Designated Fund	3,724		(3,724)		0
	578,872	1,828,492	(1,788,081)	_	619,284

Restricted Funds

Fund Purpose and restriction in use

GlaxoSmith Kline To fund a research project at Cambridge University

Astro Fund Support To fund support in particular where this relates to low grade tumours

Support Group To fund patient support
David Muir To fund a research project
Frognal Trust To fund a research project

British Toy & Hobby Trust

Childwick Trust

Brian Cross Memorial Trust

To fund a day out for children with brain tumours

To fund a research project at Royal Marsden

To fund SDBTT/UCL Centre of Excellence

To fund an information day in Wales

To fund an early diagnosis project

Jarvis (Harpenden) Trust

P F Charitable Trust

Lynn Foundation

Hedley Foundation

Vinci Plc

University of Nottingham

To fund an early diagnosis project

Oligodendroglioma Research To fund research into oligodendroglioma tumours

Broyst Foundation To fund a Patient Support Group

C Charitable Trust

To fund telephone helpline and information service and early diagnosis project

BBC Children in Need To fund a telephone helpline and information worker

Roald Dahl To fund the benign brain tumour information and support service

Big Lottery Fund To fund the brain cancer care project

CRUK To fund clinical trials

Catherine Cookson Trust

To fund a research project at Newcastle University

Joseph Foote Foundation

To fund a research project at Nottingham University

Rosetrees Trust

To fund a research project at Royal Marsden
T J Meyer Family Foundation
To fund SDBTT/UCL Centre of Excellence

Hunmanby Cancer Fund To fund a research project at Leeds

The Frognal Trust To fund a research project at Newcastle University

Vodafone Foundation To fund support and training for fundraising and customer service

Designated Funds

Designated funds are unrestricted funds earmarked by the Trustees for the payment of research grants and/or patient support costs due in less than one year.

Unrestricted Funds

In the absence of restrictions placed on income by donors, the trustees utilise funds to support the long-term foundations of the charity and its income requirements. A transfer was made from unrestricted to restricted funds to cover the research commitments. A further transfer was made to designated funds for patient support information days.

16 Pension Commitment

The charitable company operates a defined contribution scheme administered by Scottish Equitable Plc. The pension cost charges represent contributions made by the charity amounting to £20,997.98 (2010: £10,810). As at 31st March 2011, £101 (2010: £101) is included in liabilities.